Search results for "mta"

showing 10 items of 174 documents

Dental microwear texture analysis on extant and extinct sharks : Ante- or post-mortem tooth wear?

2020

Sharks are apex-predators that play an important role in past and present aquatic food webs. However, their diet - especially in extinct species - is often not well constrained. Dental microwear texture analysis (DMTA) has been successfully applied to reconstruct diet and feeding behaviours of different aquatic and terrestrial vertebrates. However, unlike in mammals, food-to-tooth contact in sharks is rather limited because only larger prey is manipulated before swallowing. Together with a fast tooth replacement rate, this reduces wear on individual teeth. Here, we present an explorative study of dental microwear texture on extant and extinct sharks to test whether ante-mortem wear is relat…

010506 paleontologyDental WearZoologyExtinct specieschemical and pharmacologic phenomenaShark teeth010502 geochemistry & geophysicsOceanography01 natural sciencesTexture (geology)DMTAZoologiPredationExtant taxonstomatognathic system14. Life underwaterEcology Evolution Behavior and Systematics0105 earth and related environmental sciencesEarth-Surface ProcessesbiologyTumbling experimentPaleontologyGeologybiology.organism_classificationstomatognathic diseasesHabitatTooth wearCarcharhinusGeologiAlterationhuman activitiesZoologyGeologyElasmobranchii
researchProduct

The effect of photodynamic therapy and polymer solution containing nano-particles of Ag /ZnO on push-out bond strength of the sealers AH-Plus and MTA…

2017

BACKGROUND The aim of this in vitrostudy was to examine and compare the effect of photodynamic therapy and solution containing nano particles Ag/ZnO on adhesion of endodontic sealers to dentinal walls of human root canal. MATERIAL AND METHODS Ninty single-rooted human teeth were selected and their clinical crown was cut from the cemento-enamel junction zone. Canals were prepared by RaCe rotary system and the smear layer was removed using 17% EDTA and 5.25% NaOCl. Samples were randomly divided into two groups of AH Plus and MTA Fillapex based on the sealer type and each group based on antimicrobial method was divided into two sub-groups of photodynamic therapy and polymer containing nano par…

0301 basic medicine030103 biophysicsScanning electron microscopeRoot canalmedicine.medical_treatmentSmear layerNanoparticleDentistryPhotodynamic therapyOperative Dentistry and Endodontics03 medical and health sciences0302 clinical medicineMTA-FillapexPush outmedicineGeneral DentistryBond strengthbusiness.industryChemistryResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.anatomical_structureUNESCO::CIENCIAS MÉDICASbusinessNuclear chemistry
researchProduct

Regulation of Dendritic Spine Morphology in Hippocampal Neurons by Copine-6.

2015

Dendritic spines compartmentalize information in the brain, and their morphological characteristics are thought to underly synaptic plasticity. Here we identify copine-6 as a novel modulator of dendritic spine morphology. We found that brain-derived neurotrophic factor (BDNF) - a molecule essential for long-term potentiation of synaptic strength - upregulated and recruited copine-6 to dendritic spines in hippocampal neurons. Overexpression of copine-6 increased mushroom spine number and decreased filopodia number, while copine-6 knockdown had the opposite effect and dramatically increased the number of filopodia, which lacked PSD95. Functionally, manipulation of post-synaptic copine-6 level…

0301 basic medicineDendritic spineVesicular Inhibitory Amino Acid Transport Proteinsdrug effects [Synapses]Tropomyosin receptor kinase BHippocampal formationgenetics [Carrier Proteins]pharmacology [Brain-Derived Neurotrophic Factor]Hippocampusmetabolism [Vesicular Inhibitory Amino Acid Transport Proteins]Mtap2 protein ratMice0302 clinical medicineNeurotrophic factorsdrug effects [Synaptic Vesicles]genetics [Nerve Tissue Proteins]Cells Culturedultrastructure [Neurons]NeuronsChemistryLong-term potentiationSynaptic Potentialsphysiology [Neurons]physiology [Dendritic Spines]Cell biologyultrastructure [Dendritic Spines]metabolism [Receptor trkB]Synaptic VesiclesFilopodiaultrastructure [Synaptosomes]Disks Large Homolog 4 ProteinMicrotubule-Associated ProteinsCognitive NeuroscienceDendritic Spinesmetabolism [Disks Large Homolog 4 Protein]Nerve Tissue Proteinsgenetics [Receptor trkB]03 medical and health sciencesCellular and Molecular NeuroscienceOrgan Culture Techniquesphysiology [Synaptic Vesicles]metabolism [Vesicular Glutamate Transport Protein 1]TrkB protein ratdrug effects [Synaptic Potentials]Synaptic vesicle recyclingAnimalsHumansReceptor trkBddc:610metabolism [Synaptosomes]metabolism [Nerve Tissue Proteins]Viaat protein ratBrain-Derived Neurotrophic Factormetabolism [Microtubule-Associated Proteins]Rats030104 developmental biologygenetics [Synaptic Potentials]nervous systemcytology [Hippocampus]Synaptic plasticityultrastructure [Synapses]SynapsesVesicular Glutamate Transport Protein 1CPNE6 protein ratphysiology [Synapses]Carrier Proteins030217 neurology & neurosurgerymetabolism [Carrier Proteins]SynaptosomesCerebral cortex (New York, N.Y. : 1991)
researchProduct

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

2020

AbstractBackgroundHER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to d…

0301 basic medicineOncologyCancer ResearchReceptor ErbB-2ApoptosisAdo-Trastuzumab EmtansineSettore MED/06chemistry.chemical_compound0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturedskin and connective tissue diseasesAged 80 and overMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisGene Expression Regulation NeoplasticSurvival RateOncology030220 oncology & carcinogenesisFemalePertuzumabmedicine.drugT-DM1 efficacymusculoskeletal diseasesAdultmedicine.medical_specialtyHER2+ breast cancer; Trastuzumab/pertuzumab blockade; T-DM1 efficacyBreast NeoplasmsAntibodies Monoclonal Humanizedlcsh:RC254-28203 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALEInternal medicinemedicineBiomarkers TumorHumansneoplasmsAgedCell ProliferationRetrospective StudiesHER2+ breast cancer; T-DM1 efficacy; Trastuzumab/pertuzumab blockadeTaxanebusiness.industryResearchCancerHER2+ breast cancerTrastuzumabmedicine.diseaseTrastuzumab/pertuzumab blockadeBlockadeLog-rank test030104 developmental biologychemistryTrastuzumab emtansineCancer cellbusiness
researchProduct

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

2021

Breast cancer (BC) heterogeneity is composite in nature, with a wide variety of factors concurring to define several pathological entities, which differ by clinical presentation, pathologic features, therapy administered, and inherent outcomes1. Additional sources of breast cancer heterogeneity may raise during the disease course. In BC patients whose disease was initially diagnosed in the early stage and subsequently progressed with metastatic involvement of one single or multiple site/s, the molecular characteristics of metastatic lesions do not necessary mimic those of the disease initially diagnosed. A well-depicted molecular landscape is crucial for subtype definition, prognostic evalu…

0301 basic medicineOncologyCancer therapyReceptor ErbB-2medicine.medical_treatmentAdo-Trastuzumab Emtansineprogesterone receptorSettore MED/060302 clinical medicinehuman epidermal growth factor receptor 2 (HER2)Antineoplastic Combined Chemotherapy ProtocolsestrogenNeoplasm Metastasisskin and connective tissue diseasesMultidisciplinaryBrain NeoplasmsQRMiddle AgedPrognosisMetastatic breast cancerNeoplasm Metastasi030220 oncology & carcinogenesisMedicineFemalePertuzumabmetastatic breast cancerReceptors ProgesteroneBreast NeoplasmHER2 positivitymedicine.drugHumanAdultmedicine.medical_specialtymedicine.drug_classSciencetrastuzumab-emtansineBreast Neoplasmsmetastatic breast cancer; HER2 positivity; cancerArticleDisease-Free SurvivalBrain Neoplasm03 medical and health sciencesBreast cancerbreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicineProgesterone receptormedicineHumanscancerbreast cancer; human epidermal growth factor receptor 2 (HER2); pertuzumab; trastuzumab-emtansine; estrogen; progesterone receptorneoplasmsAgedChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancermedicine.diseaseHER2-positiveBreast cancer; oncology; radiotherapy; chemotherapy; HER2Radiation therapy030104 developmental biologyEstrogenbusinessprognostic relevance
researchProduct

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience

2017

We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in pertuzumab-pretreated patients. We conducted a retrospective, observational study involving 23 cancer centres, and 250 patients. Survival data were analyzed by Kaplan Meier curves and log rank test. Factors testing significant in univariate analysis were tested in multivariate models. Median follow-up was 15 months and median T-DM1 treatment-length 4 months. Response rate was 41.6%, clinical benefit 60.9%. Median progression-free and median overall survival were 6 and 20 months, respectively. Overall, no differences emerged by pertuzumab pretreat…

0301 basic medicineOncologyHER2 positivereal-worldmedicine.medical_specialtyHER2 positive; T-DM1; metastatic breast cancer; previous pertuzumab; real-worldHER2 positive; Metastatic breast cancer; Previous pertuzumab; Real-world; T-DM1; OncologyT-DM1Previous pertuzumabHER2 positive; metastatic breast cancer; previous pertuzumab; real-world; T-DM1; oncologyECOG Performance Statuslaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialSettore MED/04 - PATOLOGIA GENERALElawInternal medicineMedicineUnivariate analysisSettore MED/06 - ONCOLOGIA MEDICAbusiness.industryCancerprevious pertuzumabmedicine.diseaseMetastatic breast cancerMetastatic breast cancerHER2 positive; Metastatic breast cancer; Previous pertuzumab; Real-world; T-DM1Log-rank testtrastuzumab030104 developmental biologyOncologychemistryReal-worldTrastuzumab emtansine030220 oncology & carcinogenesisHER2 positive Metastatic breast cancer Previous pertuzumab Real-world T-DM1 Oncologymetastatic breast cancerPertuzumabbusinessmedicine.drugResearch Paper
researchProduct

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

2020

Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5-24.9, 25-29.9, and 30.0-34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 70…

0301 basic medicineOncologyPhysiologyReceptor ErbB-2Clinical BiochemistryAdo-Trastuzumab EmtansineSettore MED/06body mass index; HER2-positive metastatic breast cancer; pertuzumab; trastuzumab emtansinechemistry.chemical_compound0302 clinical medicineAntineoplastic Agents ImmunologicalAged 80 and overeducation.field_of_studyUnivariate analysisMiddle AgedMetastatic breast cancerProgression-Free SurvivalQuartile030220 oncology & carcinogenesisHER2-positive metastatic breast cancerDisease ProgressionFemalePertuzumabmedicine.drugAdultmedicine.medical_specialtyPopulationBreast Neoplasmsbody mass indexAntibodies Monoclonal Humanized03 medical and health sciencesBreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicinemedicineHumansObesityeducationAgedtrastuzumab emtansinebusiness.industrynutritional and metabolic diseasesCell BiologyOverweightmedicine.disease030104 developmental biologychemistryTrastuzumab emtansineMED/06 - ONCOLOGIA MEDICAbusinessBody mass index
researchProduct

Current treatment options for HER2-positive breast cancer patients with brain metastases

2020

Abstract Brain metastases (BMs) are frequently associated with HER2+ breast cancer (BC). Their management is based on a multi-modal strategy including both local treatment and systemic therapy. Despite therapeutic advance, BMs still have an adverse impact on survival and quality of life and the development of effective systemic therapy to prevent and treat BMs from HER2 + BC represents an unmet clinical need. Trastuzumab-based therapy has long been the mainstay of systemic therapy and over the last two decades other HER2-targeted agents including lapatinib, pertuzumab and trastuzumab emtansine, have been introduced in the clinical practice. More recently, novel agents such as neratinib, tuc…

0301 basic medicineOncologymedicine.medical_specialtyPyridinesReceptor ErbB-2NeratinibTrastuzumab-emtansineBreast NeoplasmsLapatinibSystemic therapy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerQuality of lifeTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTrastuzumab deruxtecanHER2-positive breast cancerskin and connective tissue diseasesOxazolesneoplasmsTucatinibBrain Neoplasmsbusiness.industryBrain metastasesLapatinibHematologyTrastuzumabmedicine.disease030104 developmental biologyOncologychemistryTrastuzumab emtansine030220 oncology & carcinogenesisNeratinibQuality of LifeQuinazolinesPertuzumabbusinessmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

2014

Abstract Background Trastuzumab emtansine (T-DM1), a new agent developed for the treatment of HER2-positive breast cancer, is an antibody-drug conjugate with a complex compound obtained by the conjugation of trastuzumab, a stable thioether linker, and the potent cytotoxic drug maytansine-derivate(DM1), which inhibits cell division and induces cell death. Field of study PubMed database, ESMO, ASCO, San Antonio Breast Cancer Symposium Meeting abstracts and clinicaltrials.gov were searched using the terms “Anti-HER2 treatment breast cancer and trastuzumab emtansine (T-DM1) “; papers considered relevant for the aim of this review were selected. Findings/results The phase I trials have determine…

0301 basic medicineOncologymedicine.medical_specialtyReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsAdo-Trastuzumab EmtansineAntibodies Monoclonal Humanized03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerTrastuzumabInternal medicineHumansMedicineMaytansineProgression-free survivalNeoplasm Metastasisskin and connective tissue diseasesTaxanebusiness.industryCancerHematologyTrastuzumabmedicine.diseaseMetastatic breast cancerClinical trial030104 developmental biologyClinical Trials Phase III as TopicOncologychemistryTrastuzumab emtansine030220 oncology & carcinogenesisDisease ProgressionFemaleNeoplasm Recurrence Localbusinessmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Metodes angļu valodas vārdu lasīšanas prasmju attīstībai mazākumtautību skolas 1.klasē

2021

Diplomdarba nosaukums: Metodes angļu valodas vārdu lasīšanas prasmju attīstībai mazākumtautību skolas 1.klasē. Darba autore: Karīna Žantē Darba zinātniskā vadītāja: M. izgl. zin. Anita Auziņa Pētījuma mērķis: izpētīt metodes angļu valodas vārdu lasīšanas prasmju attīstībai mazākumtautību skolas 1. klasē. Pētījuma hipotēze: mazākumtautību skolas 1. klasē lasītprasme angļu valodā tiek attīstīta efektīvāk, ja tiek izmantota leksiskā pieeja un skolēni regulāri izmanto redzes un dzirdes atmiņas uzdevumus vārdu apguves procesā. Pētījuma teorētiskajā daļā ir analizētas teorētiskās atziņas par redzes un dzirdes atmiņas nozīmīgumu angļu valodas mācību procesā. Pētījuma empīriskajā daļā autore pārbau…

1. klaseIzglītības zinātnesdzirdes atmiņaredzes atmiņaefektivitātemazākumtautība
researchProduct